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ORIGINAL ARTICLE
Mutations in Potassium Channel KCND3
Cause Spinocerebellar Ataxia Type 19
Anna Duarri, PhD,1 Justyna Jezierska, MSc,1 Michiel Fokkens, BSc,1 Michel Meijer, BSc,2
Helenius J. Schelhaas, MD, PhD,3 Wilfred F. A. den Dunnen, MD, PhD,4
Freerk van Dijk, BSc,5 Corien Verschuuren-Bemelmans, MD,1 Gerard Hageman, MD,6
Pieter van de Vlies, BSc,1 Benno Ku¨sters, MD, PhD,7
Bart P. van de Warrenburg, MD, PhD,3 Berry Kremer, MD, PhD,8 Cisca Wijmenga, PhD,1
Richard J. Sinke, PhD,1 Morris A. Swertz, PhD,4 Harm H. Kampinga, PhD,9
Erik Boddeke, PhD,2 and Dineke S. Verbeek, PhD1
Objective: To identify the causative gene for the neurodegenerative disorder spinocerebellar ataxia type 19 (SCA19)
located on chromosomal region 1p21-q21.
Methods: Exome sequencing was used to identify the causal mutation in a large SCA19 family. We then screened
230 ataxia families for mutations located in the same gene (KCND3, also known as Kv4.3) using high-resolution
melting. SCA19 brain autopsy material was evaluated, and in vitro experiments using ectopic expression of wild-type
and mutant Kv4.3 were used to study protein localization, stability, and channel activity by patch-clamping.
Results: We detected a T352P mutation in the third extracellular loop of the voltage-gated potassium channel
KCND3 that cosegregated with the disease phenotype in our original family. We identified 2 more novel missense
mutations in the channel pore (M373I) and the S6 transmembrane domain (S390N) in 2 other ataxia families. T352P
cerebellar autopsy material showed severe Purkinje cell degeneration, with abnormal intracellular accumulation and
reduced protein levels of Kv4.3 in their soma. Ectopic expression of all mutant proteins in HeLa cells revealed
retention in the endoplasmic reticulum and enhanced protein instability, in contrast to wild-type Kv4.3 that was
localized on the plasma membrane. The regulatory b subunit Kv channel interacting protein 2 was able to rescue the
membrane localization and the stability of 2 of the 3 mutant Kv4.3 complexes. However, this either did not restore
the channel function of the membrane-located mutant Kv4.3 complexes or restored it only partially.
Interpretation: KCND3 mutations cause SCA19 by impaired protein maturation and/or reduced channel function.
ANN NEUROL 2012;72:870–880
Patients with a dominantly inherited spinocerebellarataxia (SCA) are characterized by a late onset, pro-
gressive atrophy of the cerebellum, affecting their motor
coordination, balance, speech, and eye coordination
movements, with many other symptoms.1 To date, 36
SCA loci have been described; for 21 of these, the corre-
sponding disease gene and causative mutation have been
identified.1–4 The majority of SCAs represent repeat
expansion diseases, including a coding CAG repeat
(SCA1–3, 6, 7, and 17) causing misfolding of the encod-
ing protein due to the expanded polyglutamine tracts, or
groups of noncoding CAG, CTG, ATTCT, and
GGCCTG repeats (SCA8, 10, 12, and 36), or large
TGGAA repeat insertions (SCA31) that induce RNA-
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mediated gain-of-function mechanisms.1 The remaining
known SCA types are caused by missense mutations or
chromosomal rearrangements (SCA5, 11, 13–15, 20, 23,
27, 28, 31, and 35) in genes displaying a wide range of
protein functions, often causing alterations in synaptic
transmission via calcium, potassium, and glutamate sig-
naling.1,5–7
We previously mapped SCA19 in a large Dutch
family (4 generations with 13 affected members) to a
region of approximately 38 Mb located in chromosomal
region 1p21-q21.8 The SCA19 locus shows significant
overlap with the SCA22 locus later reported in a single
Chinese family,9 suggesting that SCA19 and SCA22
might be caused by mutations in the same gene and lead
to an ataxia type with a worldwide distribution.10 Clini-
cal investigation and magnetic resonance imaging of our
SCA19 family revealed a relatively mild, cerebellar ataxic
syndrome with cognitive impairment, pyramidal tract
involvement, tremor and peripheral neuropathy, and
mild atrophy of the cerebellar hemispheres and vermis.11
The SCA19 locus comprises some 500 genes and tran-
scripts, but we could not identify the causative gene and
mutation by candidate gene sequencing (data unpub-
lished). We therefore applied exome sequencing to 2
affected family members and identified a novel missense
mutation in KCND3 (also known as Kv4.3) as causing
SCA19 in our family.8 Later we identified 2 different
missense mutations in this gene in 2 other families from
our Dutch ataxia cohort. Kv4.3 is a Shal-related subfam-
ily, voltage-gated potassium channel, involved in the
transient outward A-type Kþ current in the neurons. It is
highly expressed in the cerebellum.12–14 The 3 mutations
in KCND3 either impaired proper endoplasmic reticu-
lum (ER)–Golgi membrane trafficking and/or reduced
Kv4.3 channel functioning. Together, our genetic and




The participants of our original SCA19 family all gave
informed written consent, as required by the Medical Ethics
Committee of the University Medical Center Utrecht, the
Netherlands. The additional 230 ataxia patients screened in this
study were obtained from the Genome analysis laboratory,
Department of Genetics, University Medical Center Groningen.
All extended DNA analyses were performed in a diagnostic set-
ting (accredited diagnostic DNA lab). Only DNA samples from
patients who were referred for genetic testing for SCA1–3,
6–12, 14, and 17 were used. The additional tests were thus per-
formed in line with the original diagnostic request. Moreover,
patients were asked whether they agreed to their DNA being
used for future (anonymous) studies to help develop or improve
diagnostics. If they objected, this was indicated on the original
Request for DNA Test form, and their DNA was not used. The
unrelated 400 control individuals were obtained from the
Dutch blood bank. DNA was extracted from peripheral blood
by a routine salting-out procedure.
Exome Sequencing and Mutation Screening
The genomic DNA samples (individuals IV:1 and II:10 marked
by an asterisk in pedigree 1, Supplementary Fig 1A) were ran-
domly fragmented using nebulization. The resulting fragments
were bar-coded, using the standard NEBNext DNA Library Prep
Master Mix Set for Illumina (New England Biolabs, Ipswich,
MA). Fragments with an average insert size of 220bp were
amplified by polymerase chain reaction (PCR), and the quality
was verified on an Experion machine (Bio-Rad, Richmond, CA).
Exome capturing was performed using the Agilent SureSelect All
exon V2 kit. After PCR amplification of the enriched products,
paired-end sequencing was performed on a HiSeq2000 (Illumina,
San Diego, CA) with 100bp reads. Image files were processed
using standard Illumina base-calling software, and the generated
reads were ready for downstream processing after demultiplexing.
The reads were aligned to the human reference genome,
build 37, using BWA software.15 To clean the aligned data and
perform variant calling, we applied Picard duplicate removal
and the Genome Analysis Toolkit,16,17 containing quality score
recalibration, indel realignment, and an unified genotyper.
Using snpEff (http://snpeff.sourceforge.net), the variants were
annotated with information from dbSNP132, 1000 Genomes
Project (phases 1, 2, and 3), and Ensembl, build 37.64. These
programs are all integrated in our MOLGENIS Compute anal-
ysis pipeline developed by the Genomics Coordination Center,
Department of Genetics, University of Groningen (http://
wiki.gcc.rug.nl/wiki/GccStart).18 Pathogenicity predictions for
variants were obtained from PolyPhen 2.0, SIFT, and Align
GVD.19–23 Variations were validated by direct Sanger sequenc-
ing and analyzed using DNA Variant Analysis Software Muta-
tion Surveyor. The high-resolution melting technology with the
LightScanner (Idaho Technologies, Salt Lake City, UT) was
used to identify additional mutations in KCND3 according to
the manufacturer’s instructions. The primers used to amplify
the amplicons are listed in Supplementary Table 1. Aberrant
melting curves were checked by direct Sanger sequencing, and
the sequences were aligned to reference sequence NM_172198.
Postmortem Human Brain Specimens
SCA19 cerebellar tissue (hemispheres and vermis) from the
patient (individual II:1 in pedigree 1 in Supplementary Fig 1A)
with a T352P mutation and an age-matched, nondegenerative
control subject was obtained from the University Medical Cen-
ter St Radboud, Nijmegen, the Netherlands. The samples were
collected with full clearance from their Medical Ethics Commit-
tee. The frozen brain tissue was used for Western blot and
quantitative real time PCR analysis and for making paraffin-
embedded sections for histochemistry and immunohistochemis-
try tests.
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Plasmids
Wild-type KCND3 cDNA cloned into the pCMV6 plasmid
(short isoform; 636 amino acids, NM_172198) was purchased
from Origene (Rockville, MD). The cDNA was amplified using
primers (Supplementary Table 2) containing XhoI and EcoRI,
or EcoR1 and EcoRV sites, to facilitate cloning into
pcDNA3.1(), and pIRES-EGFP/Cherry plasmids, respectively.
The PCR product was first subcloned into pJET1.2/blunt (Fer-
mentas, Vilnius, Lithuania). Mutations were introduced into
the pJET-KCND3 cDNA using side-directed mutagenesis (for
primers see Supplementary Table 3) followed by further sub-
cloning into pcDNA3.1() and pIRES-EGFP/Cherry. The
pcDNA3.1-Kv4.3 plasmids were used for Western blot and
immunohistochemistry and the pIRES-Kv4.3-EGFP/mCherry
plasmids for patch-clamping. The constructs were checked for
correctness by direct sequencing. The Emerald-C1 and Emer-
ald-rat Kv channel interacting protein (KChIP) 2b/c plasmids
were kindly provided by Dr K. Takimoto (Nagaoka University
of Technology, Kamitomioka, Japan).24
Cell Culture and Transfection
HeLa and HEK293T cells were grown in Dulbecco’s Modified
Eagle’s Medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (Invitrogen) and 1% Penicillin-Strepto-
mycin (Gibco, Rockville, MD) in a 37C incubator with 5%
CO2. Cells were grown in 6-well plates for Western blot, or on
FIGURE 1: Spinocerebellar ataxia (SCA) 19 mutations lead to amino acid substitutions in highly conserved parts and domains
of Kv4.3. (A) Schematic representation of the Kv4.3 channel and the location of the 3 SCA19 mutations. Segments (S) 1 to 4
form the voltage sensor domain, and S5 and S6, together with the pore loop, form the ion-selective pore. Positively charged
residues in S4 detect the voltage change. The numbers indicate the amino acid numbers defining the beginning and end of
the transmembrane segments. The c.1054 A>C (p.T352P) mutation is located in the third extracellular loop; the c.1119 G>A
(p.M373I) and c.1169 G>A (p.S3900) mutations are located in the channel pore and the S6 transmembrane domain, respec-
tively. (B) Electropherograms of the wild-type and mutant DNA sequences (NM_172198). (C) Amino acid comparison of Kv4.3
channels across species reveals that amino acids T352, M373, and S390 are 100% conserved from human to fish.
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glass cover slips in 24-well plates for immunocitochemistry and
single-cell patch clamping for 24 hours following transfection
with polyethylenimine (Polysciences, Warrington, PA), accord-
ing to the manufacturer’s instructions.
Western Blot
After 48 hours of transfection, cell extracts and human cerebella
were homogenized using a 2% sodium dodecyl sulfate (SDS)/
phosphate-buffered saline (PBS) buffer containing protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and
sonicated. Cell and tissue lysates were centrifuged for 10
minutes at 13,000 rpm. Proteins were quantified using the
BCA kit (Thermo Fisher Scientific, Rockford, IL), and the su-
pernatant was mixed with loading sample buffer containing
10% b-mercaptoethanol and incubated for 5 minutes at 65C.
For protein analysis, 50lg of cell extract or 200lg of
brain proteins was loaded on 10% SDS-polyacrylamide gel elec-
trophoresis gel followed by immunoblot analysis. Nitrocellulose
membranes were incubated with mouse anti-Kv4.3 (K75/41;
NeuroMab, Davis, CA; 1:1,000), mouse anti-calbindin (Abcam,
Cambridge, UK; 1:2,500), mouse anti-actin (MP Biochemicals,
Solon, OH; 1:5,000), mouse anti-p53 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; 1:1,000), and mouse anti-KChIP2
(Abcam; 1:1,000). Final quantification was performed using the
program Quantity One (Bio-Rad).
Immunochemistry and Sevier–Munger Silver
Staining
After 48 hours of transfection, HeLa cells were used for immu-
nocytochemistry as previously described but with some modifica-
tions.25,26 Briefly, cells were fixed with PBS containing 4% para-
formaldehyde for 15 minutes, permeabilized, and blocked with
10% bovine serum albumin 0.1% Triton X-100 in PBS for 1
hour at room temperature. Primary and secondary antibodies
were diluted in blocking buffer and incubated overnight at 4C
and 1 hour at room temperature, respectively. The antibodies
used were: mouse anti-Kv4.3 (K75/41; NeuroMab; 1:250), rab-
bit anti-calnexin (Sigma, Milwaukee, WI; 1:200), FITC-conju-
gated goat anti-rabbit, and Cy3-conjugated anti-mouse (both
1:500; Jackson ImmunoResearch, West Grove, PA).
Cerebellar immunohistochemistry was performed on
human cerebellar tissue 10lm thick sections embedded in paraf-
fin. After deparaffination, rehydration, and antigen retrieval, tis-
sues were blocked with 10% normal goat serum in Tris-buffered
saline for 1 hour at room temperature. Primary and secondary
antibodies were diluted in blocking buffer and incubated over-
night at 4C in a humidified chamber and for 2 hours at room
temperature, respectively. The antibodies used were: rabbit anti-
Kv4.3 (Alomone Labs, Jerusalem, Israel; 1:100) and mouse anti-
calbindin (Abcam; 1:200), FITC-conjugated goat anti-mouse,
and Cy3-conjugated goat anti-rabbit (1:500, Jackson ImmunoRe-
search). All the slides were mounted in Vectashield medium with
40,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame,
CA).
For the silver staining, after deparaffination and rehydra-
tion, the cerebellar slides were placed in a 20% solution of
AgNO3 for 20 minutes at 60C. After rinsing in distilled
water, the slides were placed in a solution of 10% AgNO3 (to
which ammonia was added until the precipitate was dissolved)
þ 1 ml of 25% sodium carbonate solution. The solution was
stirred while drops of 3.7% formalin were added until the slides
stained golden brown. After being rinsed in distilled water, the
slides were placed in 5% sodium thiosulfate solution for 2
minutes. Then the slides were rinsed again, followed by dehy-
dration, xylene, and mounting.
Membrane Localization Scoring Assay
The percentage of transiently transfected HeLa cells with Kv4.3
membrane localization versus cells without membrane localization
was scored using a Leica DM IRB inverted fluorescent microscope
(Leica, Mannheim, Germany). The scoring assay was decoded and
performed in triplicate by an independent scorer. On average, a
minimum of 250 cells were counted per experiment.
Electrophysiological Measurements
Whole-cell patch clamp recording was used to quantify Kv4.3
potassium currents. All the experiments were performed at
room temperature (22–24C) using an Axopatch 200B ampli-
fier, a Digidata 1320 A interface, and pClamp version 8.2 soft-
ware (Axon Instruments, Foster City, CA). The extracellular
(bath) solution contained (mmol/l) 140 NaCl, 4 KCl, 5 glu-
cose, 2 CaCl2, 1 MgCl2, and 10 N-2-hydroxyethylpiperazine-
N0-2-ethanesulfonic acid (HEPES), and the pH was adjusted to
7.4 with NaOH. The pipette solution contained (mmol/l) 140
KCl, 10 ethylenediaminetetraacetic acid, 1 CaCl2, 1 MgCl2,
and 10 HEPES, and the pH was adjusted to 7.2 with KOH.
Microelectrodes were made of GC120F-10 borosilicate glass
(Harvard Apparatus, Holliston, MA) and pulled on a P-87
puller (Sutter Instruments, Novato, CA) having a final resist-
ance of 4 to 5MX. Series resistance was compensated by 80 to
85%. Currents were filtered at 5 kHz and digitized at 10 kHz.
Data were analyzed using Clampfit (Axon Instruments, Sunny-
vale, CA) and Excel software (Microsoft, Redmond, WA).
Results
To identify the causative gene for SCA19, the genomic
DNA of 2 affected individuals from our large Dutch fam-
ily (IV:1 and III:10 in pedigree 1 and indicated with an
asterisk in Supplementary Fig 1A) was analyzed by whole
exome capturing. An average of 3GB of sequence was gen-
erated per individual, with an average coverage depth of
70 per targeted base. At least 85% of the total target
region was covered >20. The data were filtered for sin-
gle nucleotide polymorphism (SNPs) that were not previ-
ously reported to dbSNPv132 or found in the 1000
Genomes Project (phases 1, 2, and 3), yielding 4,382 and
5,830 novel SNPs per individual (Supplementary Table 4).
Because the SCA19 disease gene had already been
mapped to 1p21-q21, further analysis focused on those
variations shared between the 2 SCA19 cases from the
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large Dutch pedigree and present within the linkage
interval. This analysis resulted in a total of 33 shared
SNPs not reported in any database (Supplementary Table
5). Of these, 25 SNPs were detected in a heterozygous
state (Supplementary Tables 6 and 7). After exclusion of
the noncoding variants, validation by Sanger sequencing,
a cosegregation check with the disease phenotype in the
original SCA19 family (Supplementary Fig 1A), and
screening of 400 Dutch blood bank controls, only one
heterozygous missense T>G variation located at chromo-
some 1:112,524,295 remained unique for SCA19 (Sup-
plementary Table 7). This variation led to a c.1054 A>C
(p.T352P) substitution in the third extracellular loop of
the voltage-gated potassium channel KCND3, also known
as Kv4.3 (Fig 1A, B).
To obtain further genetic evidence for KCND3 as the
gene underlying SCA19, we screened 230 Dutch ataxia
cases with no mutation in the known SCA genes (SCA1–
3, 6, 7, 14, 17, and 23) by high-resolution melting. This
ataxia cohort contains 30 cases with an autosomal domi-
nant (AD) inheritance pattern and 200 cases with an
unknown family history. In the probands of 2 AD families
(pedigrees 2 and 3 in Supplementary Fig 1B, C), we iden-
tified 2 novel mutations, c.1119 G>A (p.M373I) and
c.1169 G>A (p.S390N), located in the channel pore and
the S6 transmembrane domain (Fig 1A, B), respectively.
The c.1119 G>A mutation was detected in 2 affected
individuals and in 1 apparently asymptomatic carrier (Sup-
plementary Fig 1B). The segregation of the other mutation
c.1169 G>A could not be tested due to unavailability of
family members (Supplementary Fig 1C). All 3 mutated
residues of human Kv4.3 are 100% conserved between dif-
ferent species (Fig 1C). None of the KCND3 mutations
was found in 800 Dutch control chromosomes, nor in sev-
eral genetic databases (dbSNPv132, 1000 Genomes Pro-
ject, and Exome Variant Server [National Heart, Lung, and
Blood Institute Exome Sequencing Project, http://evs.gs.wa-
shington.edu/EVS/]).
The M373I proband (pedigree 2: II:1; Supplemen-
tary Fig 1B) had ambiguous neurological signs on testing
at the age of 44 years. At age 52 years, he was re-exam-
ined but was found to be without neurological symp-
toms. His father (I:1) had a progressive gait disorder
from age 55 years onward, including clear dysarthria, as
well as ataxia of the arms and of gait. Computer tomog-
raphy at that time demonstrated mild cerebellar atrophy.
Comorbid conditions included hearing impairment and
vascular atherosclerotic disease. He died at age 80 years.
This paternal father was said to have had gait instability
as well from about age 60 years onward, deceasing at age
90 years. Of the proband’s sisters, the eldest was found
to have very mild gait impairment at age 64 years, with
equivocal dysdiadochokinesia of the hands (II:3). The
youngest sister was unaffected (II:2).
The S390N proband (pedigree 3: II:1; Supplemen-
tary Fig 1C) suffered from a slowly progressive, spastic
ataxic syndrome, including dysarthria, saccadic eye move-
ments and downbeat nystagmus, cognitive impairment,
and hearing deficits. The disease symptoms started
between 30 and 35 years of age. A magnetic resonance
imaging scan of the brain revealed cerebellar vermis atro-
phy. In addition, his brother and mother were diagnosed
with the same disease.
Kv4.3 has been reported to be expressed in the cere-
bellum,14,26 and immunohistochemistry of autopsy material
from control cerebellum revealed a weak, punctuated stain-
ing of the Purkinje cell (PC) bodies, whereas a more intense
Kv4.3 signal in larger puncta was observed in the soma of
T352P mutant PCs (Fig 2A). Sevier–Munger silver staining
revealed many empty baskets indicative of PC loss (Fig 2B).
The anterior part of the vermis was most severely affected,
followed by the posterior vermis and the cerebellar hemi-
sphere. The PC loss in the hemisphere had a more patchy
appearance. The cerebellar tonsils were the least affected. In
this same order of PC loss, we observed degeneration/atro-
phy in both the molecular and internal granular layers. In
the areas with remaining PCs, axonal torpedoes were
observed. In addition, Kv4.3 protein levels in cerebellar
lysates were lower in the patient’s sample, which seemed to
be the result of PC loss as shown by the reduced PC-specific
marker calbindin expression (Fig 2C-E).
In episodic ataxia type 2, missense mutations have
already been reported as causing ER retention of the a-
subunit Cav2.1 of the P/Q voltage-activated calcium chan-
nel.27 We therefore assessed whether the SCA19 missense
mutations (T352P, M373I, and S390N) would also affect
the subcellular localization/maturation of Kv4.3. Confocal
microscopic analysis of transiently transfected HeLa cells
revealed that, unlike wild-type Kv4.3 that was mainly
located on the plasma membrane (74.5 6 3.5%; Supple-
mentary Fig 2), all 3 mutant proteins showed almost no
or markedly reduced cell surface expression (T352P, 4.9 6
0.6%; M373I, 40.4 6 6.7%; S390N, 5.0 6 2.7%; Sup-
plementary Fig 2), but rather accumulated in perinuclear
foci (Fig 3A). These data suggest that the SCA19 muta-
tions cause ER retention of Kv4.3, causing impaired traf-
ficking of the channel to the plasma membrane. Studies
showed perfect colocalization of the SCA19 mutant Kv4.3
foci and the ER marker calnexin, but not with wild-type
Kv4.3 (Fig 3B). In addition, all the Kv4.3 mutants were
more rapidly degraded, upon inhibition of protein synthe-
sis, than wild-type Kv4.3 (Fig 3C, D). The remaining
Kv4.3 protein after 9 hours of cycloheximide treatment
was 54 6 10% for wild-type versus 15 6 3%, 27 6
ANNALS of Neurology
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10%, and 16 6 4% for T352P, M373I, and S390N mu-
tant Kv4.3, respectively. The cycloheximide treatment led
to an efficient translational block, as was demonstrated
using Western blot analysis against p53 (Supplementary
Fig 3). This suggests that the SCA19 mutant proteins are
recognized as misfolded proteins and are subsequently
degraded, most likely via ER-associated degradation
(ERAD).
Functional channels do not comprise Kv4.3 alone,
because tetrameric Kv4.3 complexes form a hetero-octa-
mer complex together with the regulatory b subunits,
KChIPs, in which KChIPs drive the complex forma-
tion.28,29 Because KChIPs are absent in HeLa cells, we
wondered whether coexpression of Kv4.3 together with
KChIP could improve the ER–Golgi-plasma membrane
trafficking of the Kv4.3 mutants, as was seen for wild-
type Kv4.3 (Fig 4). On expression of KChIP2b, but not
of its inactive isoform KChIP2c, T352P and M373I
(88.8 6 1.5% and 82.6 6 1.0%) were now detected at
the plasma membrane like wild-type Kv4.3 (87.8 6
0.4%; Supplementary Fig 2). However, the mislocaliza-
tion of the S390N Kv4.3 mutant could not be rescued
by coexpression of KChIP2b, as only 21.2 6 8.4% of
the cells showed cell surface expression, but rather
trapped the regulatory b subunit in the same intracellular
compartment (Fig 4A-D). In addition, KChIPs not only
drive the tetramerization of Kv4.3 subunits, but they also
regulate Kv4.3 protein expression and stability.30,31
KChIP2b coexpression led to increased protein expres-
sion for all Kv4.3 proteins (Fig 4E) and also clearly
improved the protein stability of wild-type, T352P, and
M373I mutant Kv4.3 with the exception of S390N (Fig
4F,G). The remaining Kv4.3 protein levels after 9 hours
of cycloheximide treatment were 96 6 4% for wild-type
FIGURE 2: Immunohistochemistry, and Western blot analysis demonstrate the effect of the T352P mutation on Kv4.3 protein
expression and cerebellar degeneration in human autopsy material. (A) Control cerebellar sections stained with antibodies
against Kv4.3 (in red) and calbindin (in green) showed punctuated staining of the Purkinje cell (PC) bodies. Stronger and more
accumulated Kv4.3 staining was observed in PC soma of the spinocerebellar ataxia (SCA) 19 cerebellum of a T352P patient.
Scale bars 5 25lm. (B) Micrographs of Sevier–Munger silver stainings showing overviews (left-hand side) and details (right-
hand side) of degenerating cerebellar cortex. Note the atrophy of the folia in the vermis with empty baskets or torpedoes
(arrows). The cerebellar hemisphere was less affected, although empty baskets and torpedoes (arrows) were still encountered.
The cerebellar tonsils were least affected and showed relatively normal numbers of PCs. Scale bars: left 5 500lm, right 5
100lm. (C) Western blot analysis of cerebellar protein extracts of control and T352P Kv4.3 mutant cerebella demonstrated
markedly reduced Kv4.3 and calbindin protein levels. (D) Quantification of Kv4.3 protein levels in both control and T352P mu-
tant cerebella. Data are normalized against actin levels using Quantity One. (E) Data normalized against calbindin levels.
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Kv4.3 and 93 6 20%, 87 6 3%, and 13 6 3% for
T352P, M373I, and S390N, respectively. These data
indicate that KChIP2b can ameliorate the folding defect
of the SCA19 mutant proteins (except that of S390N)
and thereby prevent protein degradation.
To test for Kv4.3 channel activity in the presence
of KChIP2b, we recorded their Kþ currents by patch
clamping in HEK293T cells. Activation of the wild-type
Kv4.3–KChIP2b complex was detected at approximately
40 mV followed by more positive potentials up to
þ28 mV Fig 5A. In contrast, almost no detectable chan-
nel activity was detected for T352P–KChIP2b Fig 5B or
(B) and S390N–KChIP2b Fig 5D or (D) complexes (1%
and 13% channel activity compared to wild type
[100%]), whereas strongly reduced activity (up to 75%)
was measured for M373I–KChIP2b Fig 5C or (C). All
FIGURE 3: Endoplasmic reticulum (ER) retention and enhanced protein degradation of SCA19 mutant Kv4.3. (A) Confocal
images of HeLa cells expressing wild-type (WT) or T352P, M373I, and S390N mutant Kv4.3 subunits. All Kv4.3 mutants clearly
showed intracellular retention in the perinuclear region with only 4.9% (T352P), 40.4% (M373I), and 5.0% (S390N) membrane-
expressing cells, whereas the WT Kv4.3 channel was mainly expressed on the cell surface (74.5% of the cells) detected using
anti-Kv4.3 (in red). The quantification of the membrane localization is shown in Supplementary Fig 2. (B) Colocalization with
the ER marker calnexin (in green) revealed that all T352P, M373I, and S390N mutant Kv4.3 proteins (in red) were retained in
the ER, as was shown by the merged picture (in yellow). Scale bars 5 20lm. (C) Time course protein degradation experiments
were performed in HeLa cells transfected with either WT or T352P, M373I, and S390N mutant Kv4.3 treated with the protein
synthesis inhibitor cycloheximide (CHX; 100lg/ml) for the indicated time periods, and the existing cellular pool of all Kv4.3
was detected by Western blot. The pool of T352P, M373I, and S390N mutant Kv4.3 proteins was degraded more rapidly than
WT Kv4.3, which is a characteristic of misfolded ER-retained proteins. (D) Quantification of the Western blot degradation
experiment normalized by actin, showing the percentage of remaining protein in time. The graphs show the average of 3 inde-
pendent experiments, and the error bars represent the standard deviation (SD; mean 6 SD).
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FIGURE 4: The regulatory b subunit Kv channel interacting protein 2b (KChIP2b) rescues the trafficking and stability of T352P
and M373I mutant Kv4.3 channels. (A–D) Confocal images of HeLa cells expressing wild-type (WT) or T352P, M373I, and
S390N mutant Kv4.3 subunits detected using anti-Kv4.3 antibody (in red), coexpressed with either empty control Emerald-C1
(Emd), Emd-KChIP2b, or the nonfunctional isoform Emd-KChIP2c (in green). Only KChIP2b expression resulted in a marked
change in subcellular distribution of T352P (B) and M373I (C) mutant Kv4.3, as the remaining intracellular Kv4.3 pool was no
longer associated with the endoplasmic reticulum, but showed a significant increase in cell surface expression up to 88.8%
(T352P) and 82.6% (M373I) of cells (merge in yellow). (D) In contrast, almost no effect of KChIP2b on the subcellular distribu-
tion of S390N mutant Kv4.3 was detected, as now only 21.2% of cells showed Kv4.3 cell surface expression. The quantification
of the membrane localization is shown in Supplementary Fig 2. Scale bars 5 20lm. (E) Western blot data showed that
KChIP2b is able to regulate the expression levels of WT and all spinocerebellar ataxia 19 mutant Kv4.3 proteins in HeLa cells,
as for all Kv4.3 proteins increased Kv4.3 levels were detected in the presence of KChIP2b. C 5 empty control Emerald-C1; 2b
5 KChIP2b. (F) Time course for Kv4.3 protein degradation experiment. Western blot showed that coexpression of WT, T352P
and M373I mutant Kv4.3 with KChIP2b resulted in a significant increase in protein stability (rescue up to almost 90% for WT,
T352P and M373I mutant Kv4.3) in HeLa cells during 9 hours of cycloheximide (CHX) treatment. This effect was not observed
for S390N mutant Kv4.3. Here, coexpression with KChIP2b led to about 13% rescue, and thus there was a similar percentage
of remaining S390N mutant Kv4.3 proteins levels without KChIP2b after 9 hours of CHX treatment. (G) Quantification of the
Kv4.3 protein degradation in the presence of KChIP2b normalized by actin using Quantity One. The graphs show the average
of 3 independent experiments, and the error bars represent the standard deviation (SD; mean 6 SD).
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mutant Kv4.3 complexes showed significantly decreased
current amplitude at 28 mV from 4,541 6 599 (wild-
type), to 44 6 27 (T352P), 1,150 6 393 (M373I), and
571 6 174 (S390N) Fig 5E, F. These results demonstrate
that although T352P mutant Kv4.3 and the regulatory b
subunit KChIP2b coassemble and are present at the
plasma membrane, the T352P–KChIP2b complex is not
functional. The M373I–KChIP2b complex seems to be
functional, but it produces Kv4.3 channels with marked
reduced activity. Notably, very weak S390N–KChIP2b ac-
tivity was detected, despite approximately all S390N–
KChIP2b complexes being ER-retained, as was observed
by microscopy. Therefore, we speculate that probably a
few S390N–KCHIP2b complexes escape the ER and reach
the plasma membrane but still yield almost no Kv4.3
channel activity. To confirm that the observed loss of chan-
nel activity is not due to enhanced T352P, M373I, or
S390N Kv4.3 protein degradation, the Kv4.3 expression
levels were checked using Western blot. No differences in
expression levels were observed between wild-type and all
mutant Kv4.3 subunits (Supplementary Fig 4).
Discussion
Our studies provide evidence that missense mutations in
KCND3 cause SCA19 by either altering Kv4.3 ER–Golgi
plasma membrane transport, leading to enhanced protein
degradation possibly by ERAD, and/or by loss of Kv4.3
channel functioning. KCND3 encodes for Kv4.3, a
highly conserved Shal-related subfamily, voltage-gated po-
tassium channel, that is known to regulate cardiac and
neuronal membrane excitability.32 KCND3 mRNA is
highly expressed in cerebellum, including PCs, basket
cells, stellate cells, and deep neurons,33 and is thought to
be important for its development.14,34 The Kv4 channel
family consists of 3 pore-forming a subunits, Kv4.1,
Kv4.2, and Kv4.3.35 These a subunits form tetrameric
channel complexes and bind regulatory b subunits,
KChIPs that change intracellular trafficking of the Kv4
channels from ER to plasma membrane and channel ac-
tivity.28,36 The neuronal Kv4 channel complex mediates
the A-type Kþ current, which is important for dendritic
excitability, somatodendritic signal integration, and long-
term potentiation (LTP).32,37–41
FIGURE 5: SCA19 mutations cause loss of Kv4.3-channel interacting protein (KChIP2b) channel complex activity and lead to
reduced outward K1 currents. (A–D) Representative whole cell potassium currents recorded in HEK293T cells transfected with
wild-type WT (A), T352P (B), M373I (C), and S390N (D) mutant Kv4.3 coexpressing KChIP2b. The traces are generated by step
depolarization of 200-millisecond duration from a holding potential of 282 mV to 128 mV. (E) The current–voltage relationship
for WT, T352P, M373I, and S390N mutant Kv4.3–KChIP2b complexes. Clearly, the T352P, M373I, and S390N mutant Kv4.3–
KChIP2b complexes showed almost no or strongly reduced channel activity. All values shown in the graph are the average of at
least 10 independent measurements, and the error bars represent the standard error of the mean (SEM; mean 6 SEM). (F) The
bar graph shows the mean peak current density at 28 mV for WT, and T352P, M373I, and S390N mutant Kv4.3–KChIP2b com-
plexes. All mutant–KChIP2b complexes showed significant reduced peak current density at 28 mV when compared to WT Kv4.3–
KChIP2b. pA/pF, picoamperes per picofarad. The significance was calculated using Student’s t-test (*p<0.05).
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KCND3 knockout mice have already been generated,
but they do not display any neurological deficits,42 prob-
ably due to redundancy of the other Kv4 family members.
This implies that the SCA19 mutants described here must
have a dominant negative action on the maturation and/or
function of the other complex members and cause a loss
of Kv4.3 function. Our S390N mutant data support such
a hypothesis, as this mutant leads to the trapping of the
regulatory b subunit in the ER.
The question remains how defects in a voltage-
gated potassium channel can lead to cerebellar neurode-
generation. We are considering 3 potential mechanisms.
First, altered dendritic excitability due to reduced A-type
Kþ currents and subsequent initiation and a longer dura-
tion of action potentials might lead to changes of intra-
cellular calcium homeostasis that may trigger PC death.43
Second, SCA19 mutations could induce LTP deficits at
the PC synapse. This would affect one of the important
tasks of the cerebellum, fine adjustment of motor coordi-
nation, which requires intact long-term depression and
LTP processes.44,45 Third, the misfolded Kv4.3 channels
may lead to a chronic form of ER stress and overinduc-
tion of the unfolded protein response, thereby activating
proapoptotic factors leading to PC cell death.46
The different SCA19 mutations were found to
affect Kv4.3 ER–Golgi plasma membrane maturation
and channel activity differently, ranging from an almost
complete inability to reach the plasma membrane
(S390N) to almost complete absent (T352P) or only
markedly reduced (M373I) channel activity. This may, to
some extent, explain the diverse disease phenotypes
observed in the 3 SCA19 families. The patients with the
T352P and S390N mutations showed more severe dis-
ease phenotypes than those with the M373I mutation,
given the presence of cognitive impairment, myoclonus,
and tremor in most of the T352P patients, cognitive
impairment and spasticity in the S390N case, and ab-
sence of these symptoms in M373I cases. In addition,
the age of onset of the M373I family is relatively late
(average of 55 years) compared to an average 30 or 35
years of age in the T352P and S390N cases.
Interestingly, the 3 different cellular phenotypes of
the mutants are partially reminiscent of what is seen for
mutations in the cyclic adenosine monophosphate–regu-
lated chloride channel (CFTR) mutations that cause cystic
fibrosis, and in which both CFTR maturation defects and
reduced channel activities were also found.47 Different
therapeutic strategies that interfere with either the folding
or degradation of maturation defective mutants or stimu-
late channel opening of membrane-associated mutants
with impaired function may also be of value for the Kv4.3
mutants and are currently being investigated.
In addition to being expressed in brain, Kv4.3 is
also expressed at relatively high levels in heart tissue.
Although the SCA19 cases have not (yet) been reported to
exhibit cardiomyopathy, it is notable that rare genetic var-
iations have been associated with a gain of Kv4.3 function
that is associated with Brugada syndrome,48 implying that
Kv4.3 may well play a role in human heart disease.
In conclusion, our current findings significantly
contribute to revealing the importance of voltage-gated
potassium channels in cerebellar ataxias, including EA
type 1 and SCA13,20,49 and show that mutations in
KCND3, only required to prevent the fast repolarization
of neurons, are sufficient to cause cerebellar neurodegen-
eration. We therefore speculate that more Kv4 family
members or interacting proteins of Kv4.3 may also be
involved in the etiology of other cerebellar ataxias.
Acknowledgment
This work was funded by a Rosalind Franklin Fellowship
from the University of Groningen, the Prinses Beatrix
Foundation (W.OR10-38), and NutsOhra (1101-042).
Part of this work was performed at the University Medi-
cal Center Groningen Microscopy and Imaging Center,
which is sponsored by the Netherlands Organization for
Scientific Research (40-00506-98-9021 and 175-010-
2009-023).
We thank all the patients for their participation, J.
Senior for editing the manuscript, Dr K. Takimoto for
providing the KChIP2 plasmids, and Dr B. van de Sluis
for critically reading the manuscript.
Potential Conflicts of Interest
Nothing to report.
References
1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine
expansions and beyond. Lancet Neurol 2010;9:885–994.
2. Bakalkin G, Watanabe H, Jezierska J, et al. Prodynorphin muta-
tions cause the neurodegenerative disorder spinocerebellar ataxia
type 23. Am J Hum Genet 2010;87:593–603.
3. Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causa-
tive gene of spinocerebellar ataxias using exome sequencing.
Brain 2010;133:3510–3518.
4. Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic
GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type
of spinocerebellar ataxia accompanied by motor neuron involve-
ment. Am J Hum Genet 2011;89:121–130.
5. Carlson KM, Andresen JM, Orr HT. Emerging pathogenic path-
ways in the spinocerebellar ataxias. Curr Opin Genet Dev 2009;
19:247–253.
6. Matilla-Duenas A, Sanchez I, Corral-Juan M, et al. Cellular and
molecular pathways triggering neurodegeneration in the spinocer-
ebellar ataxias. Cerebellum 2010;9:148–166.
Duarri et al: Mutant KCND3 Causes SCA19
December 2012 879
7. Schorge S, van de Leemput J, Singleton A, et al. Human ataxias:
a genetic dissection of inositol triphosphate receptor (ITPR1)-de-
pendent signaling. Trends Neurosci 2010;33:211–219.
8. Verbeek DS, Schelhaas JH, Ippel EF, et al. Identification of a novel
SCA locus (SCA19) in a Dutch autosomal dominant cerebellar
ataxia family on chromosome region 1p21-q21. Hum Genet 2002;
111:388–393.
9. Chung MY, Lu YC, Cheng NC, Soong BW. A novel autosomal
dominant spinocerebellar ataxia (SCA22) linked to chromosome
1p21-q23. Brain 2003;126:1293–1299.
10. Schelhaas HJ, Verbeek DS, van de Warrenburg BP, Sinke RJ.
SCA19 and SCA22: evidence for one locus with a worldwide dis-
tribution. Brain 2004;127:E6.
11. Schelhaas HJ, Ippel PF, Hageman G, et al. Clinical and genetic
analysis of a four-generation family with a distinct autosomal dom-
inant cerebellar ataxia. J Neurol 2001;248:113–120.
12. Serodio P, Kentros C, Rudy B. Identification of molecular compo-
nents of A-type channels activating at subthreshold potentials. J
Neurophysiol 1994;72:1516–1529.
13. Tsaur ML, Chou CC, Shih YH, Wang HL. Cloning, expression and
CNS distribution of Kv4.3, an A-type Kþ channel alpha subunit.
FEBS Lett 1997;400:215–220.
14. Serodio P, Rudy B. Differential expression of Kv4 Kþ channel sub-
units mediating subthreshold transient Kþ (A-type) currents in rat
brain. J Neurophysiol 1998;79:1081–1091.
15. Li H, Durbin R. Fast and accurate long-read alignment with Bur-
rows-Wheeler transform. Bioinformatics 2010;26:589–595.
16. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Tool-
kit: a MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res 2010;20:1297–1303.
17. DePristo MA, Banks E, Poplin R, et al. A framework for variation
discovery and genotyping using next-generation DNA sequencing
data. Nat Genet 2011;43:491–498.
18. Adamusiak T, Parkinson H, Muilu J, et al. Observ-OM and
Observ-TAB: universal syntax solutions for the integration, search
and exchange of phenotype and genotype information. Hum
Mutat 2012;33:867–873.
19. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for
predicting damaging missense mutations. Nat Methods 2010;7:
248–249.
20. Waters MF, Minassian NA, Stevanin G, et al. Mutations in voltage-gated
potassium channel KCNC3 cause degenerative and developmental
central nervous system phenotypes. Nat Genet 2006;38:447–451.
21. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm.
Nat Protoc 2009;4:1073–1081.
22. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical
study of 452 BRCA1 missense substitutions with classification of eight
recurrent substitutions as neutral. J Med Genet 2006;43:295–305.
23. Mathe E, Olivier M, Kato S, et al. Computational approaches for
predicting the biological effect of p53 missense mutations: a com-
parison of three sequence analysis based methods. Nucleic Acids
Res 2006;34:1317–1325.
24. Takimoto K, Yang EK, Conforti L. Palmitoylation of KChIP splicing
variants is required for efficient cell surface expression of Kv4.3
channels. J Biol Chem 2002;277:26904–26911.
25. Duarri A, Lopez de HM, Capdevila-Nortes X, et al. Knockdown
of MLC1 in primary astrocytes causes cell vacuolation: a MLC dis-
ease cell model. Neurobiol Dis 2011;43:228–238.
26. Strassle BW, Menegola M, Rhodes KJ, Trimmer JS. Light and elec-
tron microscopic analysis of KChIP and Kv4 localization in rat cere-
bellar granule cells. J Comp Neurol 2005;484:144–155.
27. Mezghrani A, Monteil A, Watschinger K, et al. A destructive inter-
action mechanism accounts for dominant-negative effects of mis-
folded mutants of voltage-gated calcium channels. J Neurosci
2008;28:4501–4511.
28. An WF, Bowlby MR, Betty M, et al. Modulation of A-type potas-
sium channels by a family of calcium sensors. Nature 2000;403:
553–556.
29. Wang H, Yan Y, Liu Q, et al. Structural basis for modulation of
Kv4 Kþ channels by auxiliary KChIP subunits. Nat Neurosci 2007;
10:32–39.
30. Trimmer JS. Regulation of ion channel expression by cytoplasmic
subunits. Curr Opin Neurobiol 1998;8:370–374.
31. Shibata R, Misonou H, Campomanes CR, et al. A fundamental role
for KChIPs in determining the molecular properties and trafficking
of Kv4.2 potassium channels. J Biol Chem 2003;278:36445–36454.
32. Hille B. Ionic channels in excitable membranes. 3rd ed. Sunder-
lands, MA: Sinauer Associates, 2001.
33. Hsu YH, Huang HY, Tsaur ML. Contrasting expression of Kv4.3, an
A-type Kþ channel, in migrating Purkinje cells and other post-mi-
gratory cerebellar neurons. Eur J Neurosci 2003;18:601–612.
34. Herrup K, Kuemerle B. The compartmentalization of the cerebel-
lum. Annu Rev Neurosci 1997;20:61–90.
35. Covarrubias M, Bhattacharji A, De Santiago-Castillo JA, et al. The
neuronal Kv4 channel complex. Neurochem Res 2008;33:
1558–1567.
36. Rhodes KJ, Carroll KI, Sung MA, et al. KChIPs and Kv4 alpha sub-
units as integral components of A-type potassium channels in
mammalian brain. J Neurosci 2004;24:7903–7915.
37. Hoffman DA, Magee JC, Colbert CM, Johnston D. Kþ channel
regulation of signal propagation in dendrites of hippocampal py-
ramidal neurons. Nature 1997;387:869–875.
38. Birnbaum SG, Varga AW, Yuan LL, et al. Structure and function of
Kv4-family transient potassium channels. Physiol Rev 2004;84:
803–833.
39. Kim J, Jung SC, Clemens AM, et al. Regulation of dendritic excit-
ability by activity-dependent trafficking of the A-type Kþ channel
subunit Kv4.2 in hippocampal neurons. Neuron 2007;54:933–947.
40. Jerng HH, Pfaffinger PJ, Covarrubias M. Molecular physiology and
modulation of somatodendritic A-type potassium channels. Mol
Cell Neurosci 2004;27:343–369.
41. Chen X, Yuan LL, Zhao C, et al. Deletion of Kv4.2 gene eliminates
dendritic A-type Kþ current and enhances induction of long-term
potentiation in hippocampal CA1 pyramidal neurons. J Neurosci
2006;26:12143–12151.
42. Niwa N, Wang W, Sha Q, et al. Kv4.3 is not required for the gen-
eration of functional Ito, f channels in adult mouse ventricles. J
Mol Cell Cardiol 2008;44:95–104.
43. Spitzer NC. Electrical activity in early neuronal development. Na-
ture 2006;444:707–712.
44. De Zeeuw CI, Yeo CH. Time and tide in cerebellar memory forma-
tion. Curr Opin Neurobiol 2005;15:667–674.
45. Jorntell H, Hansel C. Synaptic memories upside down: bidirec-
tional plasticity at cerebellar parallel fiber-Purkinje cell synapses.
Neuron 2006;52:227–238.
46. Doyle KM, Kennedy D, Gorman AM, et al. Unfolded proteins and
endoplasmic reticulum stress in neurodegenerative disorders. J
Cell Mol Med 2011;15:2025–2039.
47. Roomans GM. Pharmacological treatment of the ion transport
defect in cystic fibrosis. Expert Opin Investig Drugs 2001;10:1–19.
48. Giudicessi JR, Ye D, Tester DJ, et al. Transient outward current (I(to))
gain-of-function mutations in the KCND3-encoded Kv4.3 potassium
channel and Brugada syndrome. Heart Rhythm 2011;8:1024–1032.
49. Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia
syndrome is associated with point mutations in the human potas-
sium channel gene, KCNA1. Nat Genet 1994;8:136–140.
ANNALS of Neurology
880 Volume 72, No. 6
